Jul 2026· Saudi Journal of Medicine and Medical Sciences· Vol 14, pp. 197 - 208· 0 citations· 114 references
Medicine
TL;DR
Current evidence on the roles of miRNAs in OA is synthesized, focusing on their regulatory functions across joint tissues, including cartilage, synovium, subchondral bone, and the infrapatellar fat pad, along with their interactions with major inflammatory and degenerative signaling pathways.
Abstract
Osteoarthritis (OA) is the most prevalent degenerative joint disease and a leading cause of chronic pain and disability worldwide, particularly among aging populations. It is characterized by progressive degeneration of articular cartilage, synovial inflammation, subchondral bone remodeling, and metabolic alterations in the infrapatellar fat pad, reflecting pathology across the entire joint microenvironment. The onset and progression of OA are driven by complex interactions among mechanical stress, aging, obesity, and metabolic dysregulation, which collectively disrupt joint homeostasis. Mechanical injury and cartilage damage induce the release of damage-associated molecular patterns, activating innate immune receptors on chondrocytes and synovial cells. This promotes the production of pro-inflammatory mediators, including interleukin-1β, tumor necrosis factor-α (TNF-α), interleukin-6, and interleukin-17, which contribute to extracellular matrix degradation and cartilage deterioration. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, have emerged as key modulators in OA pathogenesis. They regulate chondrocyte proliferation, apoptosis, extracellular matrix turnover, inflammation, and osteochondral remodeling. Notably, certain miRNAs exhibit mechanosensitive properties, responding to altered biomechanical loading and translating mechanical stimuli into gene regulatory responses. This review synthesizes current evidence on the roles of miRNAs in OA, focusing on their regulatory functions across joint tissues, including cartilage, synovium, subchondral bone, and the infrapatellar fat pad. Key miRNAs such as miR-140, miR-146a, miR-27b, miR-34a, miR-155, and mechanosensitive miR-365 are discussed, along with their interactions with major inflammatory and degenerative signaling pathways. Their potential as diagnostic biomarkers and therapeutic targets is also highlighted.
Osteoarthritis (OA) is a common chronic degenerative joint disease characterized by progressive cartilage destruction, synovial inflammation, subchondral bone remodeling, and functional decline. Current treatments remain largely symptomatic and are unable to effectively halt or reverse disease progression. Increasing e...
Yujing Zhao, Xianwen Liu· Frontiers in Genetics· 0 citations
Evaluating the potential disease-modifying effects of statins in OA systematically summarizes their mechanisms of action in the synovium, cartilage, subchondral bone, and vascular-metabolic microenvironment, reviews evidence from basic and clinical studies, and discusses the principal limitations and knowledge gaps in...
Hai-Tao Dong, Xian-Xu Zhang, Yannian Luo et al.· International Immunopharmaco...· 0 citations
Osteoarthritis (OA) is among the leading causes of disability worldwide, yet its pathogenesis remains incompletely understood. Once considered a "non-inflammatory" degenerative disorder, OA is now recognized as a condition driven by chronic low-grade inflammation. Emerging evidence implicates gut dysbiosis as a modifia...
Augusto Ferrini, Alessandro Del Monaco, B. Zampogna et al.· Orthopedic Reviews· 0 citations
Results support the idea that OA is an immunometabolic disease, and it is anticipated that this approach will control the immunometabolic dialogue, slow the advancement of osteoarthritis, end the vicious cycle of inflammatory metabolic disorders, and ultimately offer a new approach to treating osteoarthritis.
Ying Gao, Lan Shen, Xiaomei Su et al.· Frontiers in Pharmacology· 0 citations
It is highlighted that future OA treatment may gradually shift from symptom-oriented management toward disease-modifying therapy based on the identification of immune endotypes, and further studies are required to validate the underlying molecular mechanisms, evaluate safety, and conduct clinical trials, thereby facili...
Tong Wang, Wei Jiang, Xing-Xu Chen et al.· Frontiers in Immunology· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.